{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:09:33Z","timestamp":1792674573210,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s12149-023-01899-w","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T09:02:18Z","timestamp":1705914138000},"page":"296-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Visual and whole-body quantitative analyses of 68\u00a0Ga-DOTATATE PET\/CT for prognosis of outcome after PRRT with 177Lu-DOTATATE"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6790-8804","authenticated-orcid":false,"given":"Masatoshi","family":"Hotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Sonni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Thin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Ciuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artineh","family":"Hayrapetian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Allen-Auerbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"issue":"3","key":"1899_CR1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, Phan AT, Raderer M, Sedl\u00e1\u010dkov\u00e1 E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u201333.","journal-title":"N Engl J Med"},{"issue":"11","key":"1899_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1056\/NEJM198609113151102","volume":"315","author":"LK Kvols","year":"1986","unstructured":"Kvols LK, Moertel CG, O\u2019Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315(11):663\u20136.","journal-title":"N Engl J Med"},{"issue":"28","key":"1899_CR3","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656\u201363.","journal-title":"J Clin Oncol"},{"issue":"9808","key":"1899_CR4","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","volume":"378","author":"ME Pavel","year":"2011","unstructured":"Pavel ME, Hainsworth JD, Baudin E, Peeters M, H\u00f6rsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005\u201312.","journal-title":"Lancet"},{"issue":"10022","key":"1899_CR5","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968\u201377.","journal-title":"Lancet"},{"issue":"1","key":"1899_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","volume":"28","author":"JC Yao","year":"2010","unstructured":"Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28(1):69\u201376.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1899_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2967\/jnumed.119.240911","volume":"61","author":"TA Hope","year":"2020","unstructured":"Hope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, Kunz PL, et al. NANETS\/SNMMI Consensus Statement on Patient Selection and Appropriate Use of (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy. J Nucl Med. 2020;61(2):222\u20137.","journal-title":"J Nucl Med"},{"issue":"24","key":"1899_CR8","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1200\/JCO.22.00176","volume":"40","author":"TA Hope","year":"2022","unstructured":"Hope TA, Pavel M, Bergsland EK. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time? J Clin Oncol. 2022;40(24):2818\u201329.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1899_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"1","key":"1899_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2967\/jnumed.117.202275","volume":"59","author":"TA Hope","year":"2018","unstructured":"Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med. 2018;59(1):66\u201374.","journal-title":"J Nucl Med"},{"issue":"3","key":"1899_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","volume":"17","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, et al. SUV of [68Ga]DOTATOC-PET\/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors. Mol Imaging Biol. 2015;17(3):313\u20138.","journal-title":"Mol Imaging Biol"},{"issue":"3","key":"1899_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.diii.2013.07.006","volume":"95","author":"M \u00d6ks\u00fcz","year":"2014","unstructured":"\u00d6ks\u00fcz M, Winter L, Pfannenberg C, Reischl G, M\u00fcssig K, Bares R, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn Interv Imaging. 2014;95(3):289\u2013300.","journal-title":"Diagn Interv Imaging"},{"issue":"10","key":"1899_CR13","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.120.256727","volume":"62","author":"C Ortega","year":"2021","unstructured":"Ortega C, Wong RKS, Schaefferkoetter J, Veit-Haibach P, Myrehaug S, Juergens R, et al. Quantitative (68)Ga-DOTATATE PET\/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with (177)Lu-DOTATATE. J Nucl Med. 2021;62(10):1406\u201314.","journal-title":"J Nucl Med"},{"issue":"12","key":"1899_CR14","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"10","key":"1899_CR15","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.2967\/jnumed.121.263441","volume":"63","author":"M Hotta","year":"2022","unstructured":"Hotta M, Gafita A, Czernin J, Calais J. Outcome of Patients with PSMA PET\/CT Screen Failure by VISION Criteria and Treated with (177)Lu-PSMA Therapy: A Multicenter Retrospective Analysis. J Nucl Med. 2022;63(10):1484\u20138.","journal-title":"J Nucl Med"},{"issue":"11","key":"1899_CR16","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23(11):1389\u201397.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1899_CR17","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, et al. Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22(8):1115\u201325.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1899_CR18","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","volume":"44","author":"MF Bozkurt","year":"2017","unstructured":"Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET\/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588\u2013601.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1899_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2967\/jnumed.114.148247","volume":"56","author":"K Herrmann","year":"2015","unstructured":"Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, Gutierrez A, et al. Impact of 68Ga-DOTATATE PET\/CT on the management of neuroendocrine tumors: the referring physician\u2019s perspective. J Nucl Med. 2015;56(1):70\u20135.","journal-title":"J Nucl Med"},{"issue":"2","key":"1899_CR20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2967\/jnumed.122.264860","volume":"64","author":"TA Hope","year":"2023","unstructured":"Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, et al. SNMMI Procedure Standard\/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. J Nucl Med. 2023;64(2):204\u201310.","journal-title":"J Nucl Med"},{"issue":"7","key":"1899_CR21","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2967\/jnumed.118.230607","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS\/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE. J Nucl Med. 2019;60(7):937\u201343.","journal-title":"J Nucl Med"},{"issue":"11","key":"1899_CR22","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1007\/s00259-019-04455-9","volume":"46","author":"A Toriihara","year":"2019","unstructured":"Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G, et al. Prognostic value of somatostatin receptor expressing tumor volume calculated from (68)Ga-DOTATATE PET\/CT in patients with well-differentiated neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;46(11):2244\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1899_CR23","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","volume":"165","author":"E Vittinghoff","year":"2007","unstructured":"Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165(6):710\u20138.","journal-title":"Am J Epidemiol"},{"issue":"9","key":"1899_CR24","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S1470-2045(20)30323-5","volume":"21","author":"L Bodei","year":"2020","unstructured":"Bodei L, Sch\u00f6der H, Baum RP, Herrmann K, Strosberg J, Caplin M, et al. Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. Lancet Oncol. 2020;21(9):e431\u201343.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1899_CR25","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2967\/jnumed.120.244798","volume":"62","author":"T Binderup","year":"2021","unstructured":"Binderup T, Knigge U, Johnbeck CB, Loft A, Berthelsen AK, Oturai P, et al. (18)F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study. J Nucl Med. 2021;62(6):808\u201315.","journal-title":"J Nucl Med"},{"issue":"3","key":"1899_CR26","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","volume":"16","author":"T Binderup","year":"2010","unstructured":"Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16(3):978\u201385.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"1899_CR27","first-page":"S219","volume":"31","author":"EP Krenning","year":"1999","unstructured":"Krenning EP, Valkema R, Kooij PP, Breeman WA, Bakker WH, deHerder WW, et al. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Ital J Gastroenterol Hepatol. 1999;31(Suppl 2):S219\u201323.","journal-title":"Ital J Gastroenterol Hepatol"},{"issue":"9","key":"1899_CR28","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.2967\/jnumed.118.223016","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. (111)In-Pentetreotide Scintigraphy Versus (68)Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden. J Nucl Med. 2019;60(9):1266\u20139.","journal-title":"J Nucl Med"},{"issue":"4","key":"1899_CR29","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00259-019-04439-9","volume":"47","author":"J Graf","year":"2020","unstructured":"Graf J, Pape UF, Jann H, Denecke T, Arsenic R, Brenner W, et al. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE. Eur J Nucl Med Mol Imaging. 2020;47(4):881\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1899_CR30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s11307-018-1252-5","volume":"21","author":"RA Werner","year":"2019","unstructured":"Werner RA, Ilhan H, Lehner S, Papp L, Zs\u00f3t\u00e9r N, Schatka I, et al. Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. Mol Imaging Biol. 2019;21(3):582\u201390.","journal-title":"Mol Imaging Biol"},{"issue":"6","key":"1899_CR31","doi-asserted-by":"publisher","first-page":"812","DOI":"10.2967\/jnumed.121.263274","volume":"63","author":"H Jadvar","year":"2022","unstructured":"Jadvar H. The VISION Forward: Recognition and Implication of PSMA-\/(18)F-FDG+ mCRPC. J Nucl Med. 2022;63(6):812\u20135.","journal-title":"J Nucl Med"},{"issue":"5","key":"1899_CR32","first-page":"731","volume":"64","author":"R Seifert","year":"2023","unstructured":"Seifert R, Telli T, Hadaschik B, Fendler WP, Kuo PH, Herrmann K. Is (18)F-FDG PET Needed to Assess (177)Lu-PSMA Therapy Eligibility? A VISION-like. Single-Center Analysis J Nucl Med. 2023;64(5):731\u20137.","journal-title":"Single-Center Analysis J Nucl Med"},{"issue":"11","key":"1899_CR33","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.2967\/jnumed.119.241414","volume":"61","author":"J Zhang","year":"2020","unstructured":"Zhang J, Liu Q, Singh A, Schuchardt C, Kulkarni HR, Baum RP. Prognostic Value of (18)F-FDG PET\/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy. J Nucl Med. 2020;61(11):1560\u20139.","journal-title":"J Nucl Med"},{"issue":"1","key":"1899_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00259-011-1937-3","volume":"39","author":"JM Beauregard","year":"2012","unstructured":"Beauregard JM, Hofman MS, Kong G, Hicks RJ. The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39(1):50\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1899_CR35","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1677\/ERC-09-0078","volume":"17","author":"DJ Kwekkeboom","year":"2010","unstructured":"Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17(1):R53-73.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"1899_CR36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2967\/jnumed.118.215848","volume":"60","author":"J Zhang","year":"2019","unstructured":"Zhang J, Kulkarni HR, Singh A, Niepsch K, M\u00fcller D, Baum RP. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients. J Nucl Med. 2019;60(3):377\u201385.","journal-title":"J Nucl Med"},{"issue":"2","key":"1899_CR37","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1530\/ERC-18-0424","volume":"26","author":"EA Carlsen","year":"2019","unstructured":"Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocr Relat Cancer. 2019;26(2):227\u201339.","journal-title":"Endocr Relat Cancer"},{"key":"1899_CR38","doi-asserted-by":"publisher","first-page":"1141648","DOI":"10.3389\/fonc.2023.1141648","volume":"13","author":"D Su","year":"2023","unstructured":"Su D, Yang H, Qiu C, Chen Y. Peptide receptor radionuclide therapy in advanced Pheochromocytomas and Paragangliomas: a systematic review and meta-analysis. Front Oncol. 2023;13:1141648.","journal-title":"Front Oncol"},{"key":"1899_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.993182","volume":"12","author":"J Ma","year":"2022","unstructured":"Ma J, Hu X, Li L, Rao Z, Zhang C. Efficacy and safety of (177)Lu-DOTATATE targeted therapy in advanced\/metastatic pulmonary neuroendocrine tumors: A systematic review and meta-analysis. Front Oncol. 2022;12: 993182.","journal-title":"Front Oncol"},{"issue":"5","key":"1899_CR40","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000343612","volume":"7","author":"G Savelli","year":"2012","unstructured":"Savelli G, Zaniboni A, Bertagna F, Bosio G, Nisa L, Rodella C, et al. Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation. Breast Care (Basel). 2012;7(5):408\u201310.","journal-title":"Breast Care (Basel)"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-023-01899-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-023-01899-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-023-01899-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T06:18:49Z","timestamp":1710915529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-023-01899-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1899"],"URL":"https:\/\/doi.org\/10.1007\/s12149-023-01899-w","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"assertion":[{"value":"27 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors report that no potential conflicts of interest relevant to this article exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}